Pomalidomide ( DrugBank: Pomalidomide )


5 diseases
IDDisease name (Link within this page)Number of trials
28Systemic amyloidosis9
51Scleroderma6
85Idiopathic interstitial pneumonia1
227Osler disease2
331Idiopathic multicentric castleman disease1

28. Systemic amyloidosis


Clinical trials : 267Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

51. Scleroderma


Clinical trials : 525Drugs : 565 - (DrugBank : 148) / Drug target genes : 114 - Drug target pathways : 217 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

85. Idiopathic interstitial pneumonia


Clinical trials : 627Drugs : 443 - (DrugBank : 120) / Drug target genes : 99 - Drug target pathways : 212 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

227. Osler disease


Clinical trials : 56Drugs : 72 - (DrugBank : 21) / Drug target genes : 23 - Drug target pathways : 136 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

331. Idiopathic multicentric castleman disease


Clinical trials : 33Drugs : 41 - (DrugBank : 21) / Drug target genes : 22 - Drug target pathways : 123 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries